The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...
EET . Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership. Orion Corporation (O ...
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
Veterinarians are seen as the most trusted source of pet health advice. “Small acts of love. Big moments of life” campaign is launching on World Parasite Awareness Day to increase understanding of how ...
The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrounding bosakitug and the potential role of ...
Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increas ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
The PIPE financing is being led by Point72 with participation from existing investors, including Adage Capital Management, ADAR1 Capital Management, Affinity Asset Advisors, LLC, Ally Bridge Group, ...
As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the CyberMega Smart Treadmill across ...
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following ...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease. Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Bre ...
BV500: Entered global research collaboration with Shionogi for broad-spectrum non-tuberculous mycobacteria Successful IPO funding operations into 2028 with BV100 Phase 3 read-out by the end of 2027 ...
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results